This post was originally published on this site
WASHINGTON — The Food and Drug Administration and vaccine maker Johnson & Johnson expect to announce as early as Friday that contamination problems at a COVID-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.
Vaccine production at the plant run by contract manufacturer Emergent BioSolutions Inc.
EBS,
was halted after unsanitary conditions led to contamination of J&J
JNJ,
vaccines. The facility made vaccine substance and finished vaccine doses for J&J and AstraZeneca
AZN,
PLC.
